Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| INCY | INCYTE CORP | 2025-10-30 18:50:12 | 92.37 | -0.22 | -0.24 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCY | 0000879169 | INCYTE CORP | US45337C1027 | 549300Z4WN6JVZ3T4680 | 943136539 | Nasdaq | 8731 | Services-Commercial Physical & Biological Research | 1231 | DE | 1801 AUGUSTINE CUT-OFF | WILMINGTON | DE | 19803 | UNITED STATES | US | 3024986700 | 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803 | 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803 | INCYTE INC | pharmaceuticals | 1776 | Hervé Hoppenot | 2,617 | http://incyte.com | 9,900,000,000 | 196,130,993 | 196,322,703 | Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. | 2025-10-30 12:43:12 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 9,900,000,000 | -1,800,000,000 | -15.3846 | 193,524,350 | -31,001,778 | -13.8076 |
| 2023 | 11,700,000,000 | -2,500,000,000 | -17.6056 | 224,526,128 | 1,561,110 | 0.7002 |
| 2022 | 14,200,000,000 | -1,800,000,000 | -11.25 | 222,965,018 | 1,639,829 | 0.7409 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Barry P. Flannelly | Executive Vice President | 2020 | 480,542 | 0 | 2,342,694 | 308,057 | 45,034 | 4,116,884 |
| Steven H. Stein | Chief Medical Officer, Executive Vice President | 2020 | 576,321 | 0 | 1,418,393 | 369,457 | 22,022 | 3,326,750 |
| Hervé Hoppenot | Chief Executive Officer, President | 2020 | 1,094,731 | 0 | 8,317,223 | 1,403,468 | 47,746 | 16,378,192 |
| Christiana Stamoulis | Chief Financial Officer, Executive Vice President | 2020 | 585,468 | 0 | 1,743,359 | 375,321 | 28,604 | 4,154,250 |
| Vijay Iyengar | Executive Vice President | 2020 | 552,278 | 0 | 1,418,393 | 353,299 | 40,323 | 3,304,850 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 2,617 |
| 2023 | 2,524 |
| 2022 | 2,324 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 4,241,217,000 | 3,695,649,000 | 3,394,635,000 |
| Cost Of Revenue | 312,068,000 | 254,990,000 | 206,997,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 2,606,848,000 | 1,627,594,000 | 1,585,936,000 |
| General And Administrative Expenses | 1,242,157,000 | 1,161,293,000 | 1,002,140,000 |
| Operating Expenses | 4,179,851,000 | 3,075,124,000 | 2,815,195,000 |
| Operating Income | 61,366,000 | 620,525,000 | 579,440,000 |
| Net Income | 32,615,000 | 597,599,000 | 340,660,000 |
| Earnings Per Share Basic | 0.16 | 2.67 | 1.53 |
| Earnings Per Share Diluted | 0.15 | 2.65 | 1.52 |
| Weighted Average Shares Outstanding Basic | 207,110,000 | 223,628,000 | 222,004,000 |
| Weighted Average Shares Outstanding Diluted | 210,530,000 | 225,928,000 | 223,958,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,687,829,000 | 3,213,376,000 | 2,951,422,000 |
| Marketable Securities Current | — | 442,667,000 | 287,543,000 |
| Accounts Receivable | 853,154,000 | 743,557,000 | 644,879,000 |
| Inventories | 58,872,000 | 62,972,000 | 41,995,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 3,239,030,000 | 4,645,402,000 | 4,092,850,000 |
| Marketable Securities Non Current | — | 187,716,000 | 133,676,000 |
| Property Plant And Equipment | 763,411,000 | 751,513,000 | 739,310,000 |
| Other Assets Non Current | 10,848,000 | 52,107,000 | 25,435,000 |
| Total Assets Non Current | 2,205,292,000 | 2,136,705,000 | 1,748,134,000 |
| Total Assets | 5,444,322,000 | 6,782,107,000 | 5,840,984,000 |
| Accounts Payable | 197,465,000 | 109,601,000 | 277,546,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 58,865,000 | 73,325,000 | 72,047,000 |
| Total Liabilities Current | 1,641,847,000 | 1,240,379,000 | 1,157,077,000 |
| Long Term Debt | 0 | 0 | — |
| Other Liabilities Non Current | 167,543,000 | 149,151,000 | 99,243,000 |
| Total Liabilities Non Current | 354,847,000 | 351,891,000 | 313,788,000 |
| Total Liabilities | 1,996,694,000 | 1,592,270,000 | 1,470,865,000 |
| Common Stock | 193,000 | 224,000 | 223,000 |
| Retained Earnings | -1,072,881,000 | 160,385,000 | -437,214,000 |
| Accumulated Other Comprehensive Income | -13,121,000 | 13,106,000 | 15,069,000 |
| Total Shareholders Equity | 3,447,628,000 | 5,189,837,000 | 4,370,119,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 89,248,000 | 82,660,000 | 67,855,000 |
| Share Based Compensation Expense | 266,058,000 | 215,889,000 | 188,420,000 |
| Other Non Cash Income Expense | 9,053,000 | -22,579,000 | -17,366,000 |
| Change In Accounts Receivable | 111,586,000 | 98,678,000 | 28,579,000 |
| Change In Inventories | 127,633,000 | 170,151,000 | 67,504,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 88,159,000 | -167,945,000 | 105,436,000 |
| Change In Other Liabilities | 278,939,000 | 230,614,000 | 220,196,000 |
| Cash From Operating Activities | 335,337,000 | 496,487,000 | 969,941,000 |
| Purchases Of Marketable Securities | 258,370,000 | 456,020,000 | 79,860,000 |
| Sales Of Marketable Securities | 231,269,000 | 305,784,000 | 79,151,000 |
| Acquisition Of Property Plant And Equipment | — | — | 77,833,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 157,517,000 | -207,677,000 | -78,542,000 |
| Tax Withholding For Share Based Compensation | 40,302,000 | 28,550,000 | 26,301,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 49,301,000 | 35,836,000 | 61,115,000 |
| Repurchase Of Common Stock | 2,023,975,000 | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -2,021,547,000 | -20,033,000 | -794,000 |
| Change In Cash | -1,525,770,000 | 262,101,000 | 893,960,000 |
| Cash At End Of Period | 1,687,829,000 | 3,213,376,000 | 2,951,422,000 |
| Income Taxes Paid | 373,056,000 | 378,206,000 | 136,242,000 |
| Interest Paid | — | 2,551,000 | 2,666,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.16 | 2.67 | 1.53 |
| Price To Earnings Ratio | 431.6875 | 23.5169 | 52.4967 |
| Earnings Growth Rate | -94.0075 | 74.5098 | -64.4186 |
| Price Earnings To Growth Ratio | -4.5921 | 0.3156 | -0.8149 |
| Book Value Per Share | 16.6464 | 23.2075 | 19.6849 |
| Price To Book Ratio | 4.1493 | 2.7056 | 4.0803 |
| Ebitda | 497,199,000 | 1,061,016,000 | 547,423,000 |
| Enterprise Value | 12,617,258,700 | 10,828,226,120 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0 | 0 | — |
| Capital Expenditures | 101,146,000 | 94,863,000 | 83,245,000 |
| Free Cash Flow | 234,191,000 | 401,624,000 | 886,696,000 |
| Return On Equity | 0.0095 | 0.1151 | 0.078 |
| One Year Beta | 0.4583 | 0.4648 | 0.5594 |
| Three Year Beta | 0.5154 | 0.5818 | 0.6462 |
| Five Year Beta | 0.6133 | 0.6452 | 0.7481 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel | 2025-10-15 | 277 | A | 26,846 |
| Denton Sheila A. | EVP & General Counsel | 2025-10-15 | 277 | D | 26,569 |
| Denton Sheila A. | EVP & General Counsel | 2025-10-15 | 277 | D | 9,161 |
| Denton Sheila A. | EVP & General Counsel | 2025-10-03 | 3,501 | D | 26,569 |
| Denton Sheila A. | EVP & General Counsel | 2025-10-02 | 599 | A | 33,799 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Shelley M Capito | Senator | 2018-12-08 | Sale (Full) | 2018-11-12 | Spouse | $1,001 - $15,000 |
| Shelley M Capito | Senator | 2017-10-06 | Purchase | 2017-09-08 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Rob Bresnahan | 2025-05-31 | PA08 | Sale | 2025-05-15 | — | $1,001 - $15,000 |
| Daniel Goldman | 2023-04-17 | NY10 | Sale | 2023-03-06 | — | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 3,600,522 | 42,454 | 84.81 |
| GRANDFIELD & DODD, LLC | 2025-09-30 | 1,787,540 | 21,077 | 84.81 |
| iA Global Asset Management Inc. | 2025-09-30 | 1,493,000 | 17,606 | 84.8006 |
| Parkside Financial Bank & Trust | 2025-09-30 | 38,080 | 449 | 84.8107 |
| STRS OHIO | 2025-09-30 | 320,836 | 3,783 | 84.8099 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SOUND SHORE FUND INC | 2025-09-30 | Institutional Class | SSHVX | 254,125 | 21,552,341.25 | 2.2309 |
| SOUND SHORE FUND INC | 2025-09-30 | Investor Class | SSHFX | 254,125 | 21,552,341.25 | 2.2309 |
| SHELTON FUNDS | 2025-08-31 | K Shares | SPXKX | 937 | 79,279.57 | 0.0264 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | SPFIX | 937 | 79,279.57 | 0.0264 |
| Tidal Trust III | 2025-08-31 | Azoria 500 Meritocracy ETF | SPXM | 80 | 6,768.8 | 0.0198 |